Tanezumab In Osteoarthritis Of The Knee (2)

Model scores of the 29,894 trials active now.

Model score 14% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (734 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2010-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 16.4% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Drug's FAERS reports marked serious: 59.6% (lowers risk) · Drug's FDA history
• Phase: 3 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 339 (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: placebopfcardiacpaingreater than
  Phrases that lowered it: and safetyefficacy andsafety ofkneethe efficacy
• Drug's FAERS reports with a death: 7.2% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 554 (raises risk) · Sponsor's track record
• Disease area, neurology: Yes (raises risk) · Disease area
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Number of arms: 4 (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Tanezumab in Osteoarthritis of the Hip or Knee (2) NCT00863304 · started 2009 · scored riskier than 32% of active trials completed
• Tanezumab In Osteoarthritis Of The Hip Or Knee NCT00985621 · started 2009 · scored riskier than 63% of active trials terminated
• Tanezumab in Osteoarthritis of the Knee NCT00733902 · started 2008 · scored riskier than 98% of active trials completed
• Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip NCT00809354 · started 2009 · scored riskier than 89% of active trials terminated
• Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study NCT01089725 · started 2010 · scored riskier than 74% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.